Today's Highlights
Premium
The FDA approved Neurocrine’s & AbbVie’s Endometriosis drug, Orilissa. Neurocrine stock met & surpassed the Prohost 2018 target
AbbVie (NYSE: ABBV) , in cooperation with Neurocrine Biosciences (NBIX) , announced that the United States FDA approved Orilissa ™ (elagolix) under priority review for women with moderate to severe en...
P
Prohost Biotech
1 min read
25
0
Unlock Premium Content
This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.
Unlimited articles
Expert analysis
Research reports
Comments (0)
Please sign in to join the discussion